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ABSTRACT
Objective: To determine if amnioinfusion with an antibiotic solution decreased the rate of clinical
chorioamnionitis and puerperal endometritis in patients with meconium-stained amniotic fluid.
Methods: Patients in labor at 36 weeks of gestation or greater with singleton pregnancies and
meconium-stained amniotic fluid were randomized to receive either cefazolin, 1 g/l,000 mL, of
normal saline (n 90) or normal saline (n 93) amnioinfusion. Rates of clinically diagnosed
chorioamnionitis and endometritis and of suspected and culture-proven neonatal infection were
determined.
Results: Between the study and control groups, the incidences of clinical chorioamnionitis (7.8%
vs. 8.6%), endometritis (2.4% vs. 3.5%), aggregate intrauterine infection (10.0% vs. 11.8%), sus-
pected neonatal infection (17.8% vs. 21.5%), and proven neonatal infection (0.0% vs. 2.2%) were
not significantly different.
Conclusions: Prophylactic use of cefazolin in amnioinfusions did not significantly reduce rates of
maternal or neonatal infection in patients with meconium-stained amniotic fluid. Infect. Dis. Obstet.
Gynecol. 7:153-157, 1999. (C) 1999Wiley-Liss, Inc.
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econium aspiration syndrome, an uncommon
but serious neonatal complication, occurs
most often in term or postterm infants who pass
meconium in utero. Meconium-stained amniotic
fluid (MSAF) complicates 8-16% of all deliveries.
Though controversial in the absence of variable
decelerations, z amnioinfusion is standard treat-
ment for patients with MSAF at our institution and
others. By diluting meconium, amnioinfusion has
been associated with decreased frequency of thick
meconium,3,4 less meconium below the neonate’s
vocal cords,3-s and a decrease in the rate of meco-
nium aspiration syndrome.3,6,8
Meconium has also been identified as a risk fac-
tor for microbial invasion of the amniotic cavity. 7,8
In vitro, it has been found to enhance bacterial
growth9,1 and impair immune function. 11 Clini-
cally, meconium is associated with an increased in-
cidence of chorioamnionitis 11-a4 and endometri-
tis.3,4
One study has shown a significant reduction in
the rate of clinical chorioamnionitis when intrave-
nous ampicillin-sulbactam was administered pro-
phylactically for the indication of MSAF. 15 Since
amnioinfusion is utilized in the setting of MSAF,
and meconium is an identified risk factor for infec-
tion, we thought it logical to investigate the utility
of antibiotics in the amnioinfusate. Additionally,
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true antibiotic prophylaxis should employ an inex-
pensive, nontoxic agent that has reasonable activity
against most pelvic pathogens. Accordingly, we de-
signed a prospective, randomized, double-blinded,
placebo-controlled trial to assess the efficacy of
prophylactic cefazolin added to amnioinfusions ad-
ministered for MSAF.
SUBJECTS AND METHODS
From September 11, 1996, to March 16, 1998, pa-
tients at Shands Hospital who had MSAF diag-
nosed after rupture of membranes were evaluated
for participation. The study was approved by the
University of Florida Health Center Institutional
Review Board. Patients meeting study criteria were
asked to participate, and, if they were willing, writ-
ten informed consent was obtained.
Inclusion criteria were 1) labor, 2) singleton ges-
tation, 3) 36 weeks or greater gestational age, 4) live
fetus, and 5) MSAF deemed by the patient’s phy-
sician to be of sufficient thickness to administer an
amnioinfusion for the purpose of prophylaxis
against meconium aspiration syndrome. Patients
were excluded from enrollment if they 1) were al-
lergic to cefazolin or had a history of an anaphylac-
tic reaction to penicillin, 2) had been diagnosed
with chorioamnionitis prior to being diagnosed
with MSAF, or 3) had a contraindication to labor.
Group assignment was determined by means of
a computerized random number generator. A vial
of either one gram of cefazolin powder or 15 mL of
normal saline was placed in numbered opaque en-
velopes by the hospital’s research pharmacist.
These envelopes were maintained in a central lo-
cation in the labor and delivery suite. Once a sub-
ject was deemed eligible and gave consent for
study participation, the physician caring for the pa-
tient provided the next envelope in sequence to
the patient’s nurse, who mixed the vial into one
liter of normal saline. The patient, her physician,
and the investigators were blinded to the patient’s
group assignment.
Amnioinfusions were administered according to
a standard protocol used at our institution. Ambient
temperature normal saline was infused through an
intrauterine pressure catheter using gravity drain-
age. After an initial bolus dose of 200 mL, the pa-
tient’s nurse assessed fluid return, uterine tonus,
and fluid character. As long as some return was
seen, baseline uterine tone was below 15 mmHg,
and the fluid return was not yet clear, the amnio-
infusion was continued. These variables were re-
assessed after every 100 mL of amnioinfusion.
Patients requiring cesarean delivery received
one gram of cefazolin intravenously at cord clamp-
ing and a second dose 8 hours later. This was due
to the fact that all patients enrolled had at least one
risk factor for endometritis, namely MSAF.
The primary outcome measures were the occur-
rence of either clinical chorioamnionitis or puer-
peral endometritis. The incidence of aggregate ma-
ternal infection (clinical chorioamnionitis plus en-
dometritis) was calculated for each group. Other
outcome variables were suspected neonatal infec-
tion, as evidenced by the neonate receiving intra-
venous ampicillin and gentamicin pending culture
results, and culture-proven neonatal infection.
Clinical chorioamnionitis was diagnosed based
on the presence of one or more of the following:
maternal temperature of 38C or greater, maternal
or fetal tachycardia, uterine tenderness, or foul-
smelling amniotic fluid. The diagnosis of puerperal
endometritis was also made clinically in patients
with temperature over 38C on two occasions post-
partum, uterine tenderness, and/or foul-smelling
lochia in the absence of other localizing signs of
infection. Patients who had clinical chorioamnion-
itis and persistent fever postpartum were not also
considered to have endometritis.
Sample size calculations assumed a rate of ag-
gregate maternal infection of 40% (based on inci-
dences in the literature1,lz,13,1s,17,18) and a 50%
reduction in infection rate with antibiotic prophy-
laxis. For a significance level of a type-I error of
0.05 and a type-II error of 0.2, 93 subjects in each
study arm were necessary. Statistical analysis was
performed with the use of the uncorrected chi-
square and Fisher exact test for proportional data as
appropriate, and the unpaired, two-tailed t-test was
used for continuous variables. Ninety-five percent
confidence intervals were calculated for discrete
outcome variables.
RESULTS
Over the 18-month study period, 200 patients were
enrolled and randomized, 100 each to the cefazolin
and placebo groups. Seventeen patients were ex-
cluded from data analysis. Three of these patients
delivered before amnioinfusion could be adminis-
tered, two received intravenous antibiotics for sub-
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TABLE I. Demographic and clinical profile of
study patients
Cefazolin Placebo
(n 90) (n 93)
Age (yr) 24.2 + 6. 23.7 + 5.7
Nulliparity 26 (28.9%) 37 (39.8%)
Race
White 45 (50.0%) 35 (37.6%)
Black 35 (38.9%) 46 (49.5%)
Other 10 (I I. I%) 12(I 2.9%)
Gestational age (wk) 39.8 + i.3 39.5 + 1.2
Duration of ROM (h) 6.7 + 5.6 7.6 + 8.8
Duration of labor (h) 13.5 + 6.7 13.9 + 8.2
Thick meconium
(vs. moderate or unspecified) 48 (53.3%) 47 (50.5%)
More than 4 vaginal
exams after ROM 26 (28.9%) 29 (31.2%)
Infant’s birth weight (g) 3,432 + 453 3,421 +/- 471
Delivery
Spontaneous vaginal 63 (70.0%) 60 (64.5%)
Operative vaginal 0 I. 1%) 14 15. 1%)
Cesarean 17 (I 8.9%) 19 (20.4%)
GBS prophylaxis 21 (23.3%) 22 (23.7%)
aROM, rupture of membranes. Data are presented as n (%) or mean +/-
standard deviation. None of the observed differences were statistically
significant.
acute bacterial endocarditis prophylaxis, and
twelve others had protocol violations. Of those re-
maining, 90 patients received amnioinfusions con-
taining cefazolin, and 93 received normal saline
placebo. No untoward effects of amnioinfusion
were noted in either group.
Groups were similar with respect to demo-
graphic variables and with respect to labor and de-
livery characteristics known to be associated with
chorioamnionitis and endometritis (Table 1). Since
all patients received amnioinfusions, all had intra-
uterine pressure catheters.
Analysis of the primary outcome variables dem-
onstrated similar rates of clinical chorioamnionitis
and endometritis in the cefazolin and placebo
groups (Table 2). The rates of aggregate maternal
infection were also similar between the groups.
Note that the denominators for endometritis are
smaller than for clinical chorioamnionitis. This dif-
ference is due to the fact that we did not consider
a patient who had clinical chorioamnionitis and
then experienced persistent fevers postpartum to
also have endometritis. Differences between
groups in the rates of suspected and confirmed
neonatal infection were also not statistically signifi-
cant (Table 2). The two cases of confirmed neona-
tal infection were infants with positive blood cul-
TABLE 2. Outcome variables
Cefazolin Placebo
n=90 n=93
Chorioamnionitis 7 (7.8, 5.0-10.6) 8 (8.6, 5.7-11.5)
Endometritis 2 (2.4, 0.7-4. I) 3 (3.5, 1.5-5.5)
Aggregate maternal
infection 9(10.0,6.8-13.2) II (11.8,8.5-15.1)
Suspected neonatal
infection 16 (17.8, 13.8-21.8) 20 (21.5, 17.2-25.8)
Proven neonatal
infection 0 (0.0, 0.0-3.3) 2 (2.2, 0.7-3.7)
aData are presented as n (%, 95% confidence interval). None of the
observed differences were statistically significant.
bn 83 for the cefazolin group, and n 85 for the saline group.
tures. No other neonatal infections (e.g., meningi-
tis, pneumonia)were noted in either group.
DISCUSSION
In this study, prophylactic addition of cefazolin to
amnioinfusions in pregnancies complicated by
MSAF did not significantly reduce the rates of
clinical chorioamnionitis, endometritis, or neonatal
infection. The procedure itselfwas quite safe, how-
ever. The aggregate maternal infection rate (clini-
cal chorioamnionitis or endometritis) in the control
group was one third that expected. This effect was
due primarily to an extraordinarily low rate of pu-
erperal endometritis. Although some patients with
endometritis may have become symptomatic after
discharge, none returned to our hospital in this
manner, and a large number of such cases is un-
likely.
Although not significantly different, there was a
slightly lower percentage of infection in the cefa-
zolin group. Nevertheless, given the aggregate in-
fection rate in the control group during the study
period, a sample size of approximately 1,400 pa-
tients would be required to show a 50% reduction
in the infection rate, assuming an alpha level of
0.05 and a beta of 0.20. Therefore, a type-II error
cannot be excluded. It seems unlikely that such a
difference would be clinically significant, however,
and prophylactic antibiotics are rarely recom-
mended in situations in which the background rate
of infection does not significantly exceed 10%. 19
Several factors may explain the lower than an-
ticipated background infection rate. First, since pa-
tients undergoing cesarean delivery who were at
highest risk for endometritis received a second
dose of intravenous antibiotic prophylaxis, the en-
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dometritis rate may have been decreased. Second,
we currently employ the universal screening strat-
egy for prevention of early onset neonatal group B
streptococcal infection endorsed by the Centers for
Disease Control and Prevention. A recent report
from our institution showed that rates of clinical
chorioamnionitis and endometritis were signifi-
cantly lower with this approach, as opposed to pre-
viously employed strategies,z It is likely that a
similar trend is present in patients with MSAF.
Finally, during this study period, we screened all
pregnant patients for bacterial vaginosis in the late
second trimester and treated those women who
were infected. Such intervention may well serve to
lower the overall rates of maternal infection in our
population.
In order to test this intervention as it would be
employed clinically, we made no attempt to control
for the volume of amnioinfusion patients received.
Because many patients certainly delivered before
receiving the entire liter of amnioinfusion and
some of the antibiotic remains in suspension and
flows back out of the cervix, the dose of cefazolin
delivered was likely less than one gram, and a
larger amount of cefazolin in the suspension may
have been more efficacious.
As stated previously, intravenous ampicillin-
sulbactam given prophylactically in this setting has
been shown to significantly reduce the rate of clini-
cal chorioamnionitis. 15 However, utilization of
more narrow spectrum agents for prophylaxis
seems prudent, since broad-spectrum agents used
in this manner may select for resistant and more
virulent strains of microorganisms.
Cefazolin added prophylactically to amnioinfu-
sions administered for MSAF did not significantly
reduce the rates of maternal or neonatal infection
in this study. Further investigation is needed to
elucidate the appropriate role, if any, for antibiotic
prophylaxis in patients with this condition.
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